These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17055409)

  • 21. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology.
    van der Greef J; McBurney RN
    Nat Rev Drug Discov; 2005 Dec; 4(12):961-7. PubMed ID: 16341061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scientific harassment by pharmaceutical companies: time to stop.
    Hailey D
    CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug evaluation: new requirements and perspectives].
    Addis A; Rocchi F
    Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 29. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
    Ben-Asher D; Juris M
    J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
    [No Abstract]   [Full Text] [Related]  

  • 30. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 35. Medicines regulation and health technology assessment.
    Breckenridge A; Woods K; Walley T
    Clin Pharmacol Ther; 2010 Feb; 87(2):152-4. PubMed ID: 20107448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative risk modelling for new pharmaceutical compounds.
    Tang Z; Taylor MJ; Lisboa P; Dyas M
    Drug Discov Today; 2005 Nov; 10(22):1520-6. PubMed ID: 16257374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription.
    Verhagen CC; Niezink AG; Engels YY; Hekster YY; Doornebal JJ; Vissers KC
    Pain Pract; 2008; 8(3):157-63. PubMed ID: 18373512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Innovation or pseudo-innovation: that is the question].
    Unger T
    Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.